Navigation Links
Cardio3 BioSciences, a European biopharmaceutical company, now covered by Edison Investment Research
Date:1/8/2014

LONDON, Jan. 8, 2014 /PRNewswire/ -- Edison's comprehensive report on Cardio3 BioSciences, Healing failing hearts, analyses its C-Cure heart regenerative product, which uses a mix of powerful cell-signalling molecules to programme autologous stem cells to develop into heart muscle. This makes C-Cure a potentially powerful novel treatment for patients with weakened, scarred hearts, usually due to previous heart attacks. C-Cure showed positive efficacy endpoints in Phase II and median heart output increased by 25% relative to baseline. The CHART-1 Phase III in chronic ischaemic heart failure is underway using C-Cathez delivery to improve cell retention 3.6 fold. Data are expected in late 2015.

Based on clinical probabilities of EU 40% and US 25%, our healthcare team identifies the base case indicative value as €77 per share. Scenario risk variants range from €42 to €225 per share.

For the full report see: www.edisoninvestmentresearch.com/research/company/cardio3-biosciences

Keywords: Cardio3 BioSciences, C-Cure, autologous stem cell therapy, ischaemic heart disease, bioscience, healthcare, Edison Investment Research.

All reports published by Edison are available to download free of charge from its website.

Overview of company: Cardio3 is developing a directed autologous stem cell therapy for chronic ischaemic heart disease. Cells are isolated from bone marrow and cultures for six to eight weeks. The product is in Phase III in the EU and on Phase III hold in the US while the FDA considers a delivery system.

About Edison: Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support its capit
'/>"/>

SOURCE Edison Investment Research
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
2. Pressure BioSciences, Inc. to Discuss Third Quarter 2013 Financial Results and Provide a Business Update
3. Regado Biosciences, Inc. Appoints World-Renowned Leader in Cardiovascular Research and Former Global Head of Cardiovascular Diseases for Merck & Co., to Board of Directors
4. Regado Biosciences, Inc. to Provide Third Quarter 2013 Financial Results
5. Jeeven BioSciences, Inc. Announces the Release of Its Neuro-XTM Serum-Free and Xeno-Free Tissue Culture Media
6. Biotechs Leading the Healthcare Sector - Alliqua, Pacific Biosciences, Oncothyreon, Keryx, Organovo
7. Regado Biosciences, Inc. to Present at Aegis Capital Vegas Healthcare Conference
8. SAGE Labs, Inc. Licenses CRISPR/Cas9 genome engineering technology from Caribou Biosciences, Inc.
9. Regado Biosciences, Inc. Announces Exercise of Over-Allotment Option
10. Pressure BioSciences, Inc. to Discuss Second Quarter 2013 Financial Results and Provide a Business Update
11. Pressure BioSciences, Inc. Closes Final Tranche of Series J Above Market Private Placement - Total Amount Raised in PIPE Slightly Exceeds $2 Million Goal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2, 2014 Orexigen Therapeutics, Inc. (Nasdaq: ... and Trademark Office (PTO) has issued a patent related ... weight loss. NB32 is a fixed-dose combination of naltrexone ... Patent No. 8,815,889 claims methods for treating insulin resistance ... expires in 2024. If NB32 is approved for use ...
(Date:9/2/2014)... ROCKVILLE, Md. , Sept. 2, 2014 /PRNewswire/ ... of novel anti-infective biologic and drug candidates targeting ... announced today positive results from its final preclinical ... Drug Administration (FDA) guidance, this bridging study was ... product candidate designed to prevent the devastating effects ...
(Date:9/2/2014)... BETHESDA, Md. , Sept. 2, 2014  Spherix ... fostering and monetization of intellectual property, today announced that ... three patents to the Company in the month of ... of patents.  The issued patents are: ... , U.S.RE45,081 issued August 19, 2014; and ...
(Date:9/1/2014)... , Sept. 1, 2014 Reportlinker.com ... available in its catalogue: India Solid ... http://www.reportlinker.com/p02350445/India-Solid-Waste-Management-Vehicles-Market-Forecast-and-Opportunities-2019.html ... are the main governing bodies responsible for complete ... cities. On an average, around 135,000 MT solid ...
Breaking Biology Technology:Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5United States Patent & Trademark Office Issues Three New Standard Essential Patents to Spherix 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 4India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 5India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 6India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 7India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 8
... Switzerland, October 5, 2011 Debiopharm Group™ ... on drug development and companion diagnostics, today presented the ... Cancer Center Research Institute in Tokyo, for his basic ... genes, and to Doctor Mineo Kurokawa from the University ...
... 4, 2011 The VENTANA anti-Helicobacter pylori (SP48) Rabbit ... H. pylori antibody to receive 510(k) ... by Ventana Medical Systems, Inc. (Ventana), a member of ... used in immunohistochemical (IHC) staining, aids in the detection ...
... JACKSONVILLE, Fla., Oct. 4, 2011 MSC Care ... and services to post-discharge and post-injury workers, compensation ... Integrated Healthcare Services, a national company also focused ... unique and comprehensive surgical implant cost management solution, ...
Cached Biology Technology:The Japanese Cancer Association and Debiopharm Group™ Present Doctors Arakawa and Kurokawa With the 2011 'JCA-Mauvernay Award' for Their Innovative and Outstanding Research in the Field of Cancer 2The Japanese Cancer Association and Debiopharm Group™ Present Doctors Arakawa and Kurokawa With the 2011 'JCA-Mauvernay Award' for Their Innovative and Outstanding Research in the Field of Cancer 3Ventana Medical Systems, Inc. Receives First FDA 510(k) Clearance for H. pylori Antibody 2Ventana Medical Systems, Inc. Receives First FDA 510(k) Clearance for H. pylori Antibody 3MSC to Offer Surgical Implant Cost Management Solution through Acquisition of Integrated Healthcare Services 2
(Date:9/2/2014)... From AGU,s blogs: Earthquake rupture through a U.S. suburb ... University of California Davis in the hours and days ... helping scientists understand why the earthquake caused so much ... The Trembling Earth blog, hosted by the American Geophysical ... Future Mars Rovers: The Next Places to Direct Our ...
(Date:9/2/2014)... September 3, The Field Museum will present the prestigious ... of his commitment to biodiversity conservation awareness. The Parker/Gentry ... an outstanding individual, team or organization whose efforts have ... natural heritage and whose actions can serve as a ... of Mongabay.com, an environmental science and conservation news website ...
(Date:9/2/2014)... Konservat-Lagersttte of lithographic limestone is well known as ... from that area (for example, Archaeopteryx). Now, for ... in the French equivalent of these outcrops - ... oldest known water treader. , Despite the abundance ... fossils have been obtained from the Late Kimmeridgian ...
Breaking Biology News(10 mins):This week From AGU: California earthquake, future Mars rovers, models underestimate ozone 2Exceptionally well preserved insect fossils from the Rhône Valley 2
... to support the theory that old cells help make ... that as these animals age, the number of aging ... cells lose their ability to divide, a state known ... advanced online edition of Science, is the first to ...
... the journal Genome Research that large segments ... mobile DNA elements called transposons. The locations of ... are enriched in genes crucial for the regulation of ... DNA sequences that have the capacity to move from ...
... SIDS (sudden infant death syndrome) in African Americans can be ... deaths result from a common genetic variation that increases an ... of environmental stress, a research team based at the University ... Journal of Clinical Investigation. , Children with two copies ...
Cached Biology News:Aging cells, aging body: Fresh evidence for a connection 2Where 'jumping genes' fear to tread 2Gene variation increases SIDS risk in African Americans 2Gene variation increases SIDS risk in African Americans 3